this IS A very GOOD STOCK WE HAVE RECOMMENDED THIS AROUND 990 levels....
here are some inputs which should help you " Aventis India with its strong presence in the lifestyle segment of cardiovascular, anti-diabetics and oncology is most likely to benefit. To put things in perspective, in the anti-diabetes segment, its brands �Amaryl� is the market leader having cornered a share of around 4%. In the cardiovascular segment, its brand �Cardace� is the largest brand in the Indian market with a share of around 28%. Moreover, the company�s product, 'Lantus' (the world�s first and only once a day insulin) has garnered a share of 6% of the insulin market.
Besides this, the strong growth rate posted by the anti-cancer drug �Taxotere� has also bolstered the company�s presence in the oncology market. We believe that these brands will continue to be the key growth drivers going forward. We, thus, expect Aventis� domestic revenues to grow at a CAGR of 9% between CY08 and CY11."
Share it on Facebook
